Cerebrolysin

Mechanism (as reported)

The provided sources report several mechanistic/proteomic and model-based claims, including: (1) proteomic analysis identifying a large set of peptides/fragments and describing that identified fragments can correspond to known biologically active peptides and can modulate the activity of multiple human signaling proteins; (2) comparative analyses suggesting that some preparations allegedly similar to Cerebrolysin differ in peptide composition and lack relevant biological activity; and (3) preclinical model discussions in which nanodelivery approaches are reported to reduce AD-like pathology markers (e.g., amyloid beta peptide, phosphorylated tau, and inflammatory mediators) in specific injury/sleep-deprivation contexts. (PMIDs: 31626174, 38737662, 37480458, 37833015, 37783554, 38737662, 37480458)

Key findings (each cites a source)

• A Cochrane review update reported that seven randomized controlled trials (1773 participants) of Cerebrolysin or Cerebrolysin-like agents started within 48 hours of acute ischaemic stroke met inclusion criteria, and it summarized risk-of-bias judgments across domains (e.g., selective outcome reporting, blinding, allocation-related domains, incomplete outcome data, and other bias). (PMIDs: 37818733) [PMID 37818733]
• In the provided Cochrane review update, all-cause death was reported as showing little to no difference with Cerebrolysin or Cortexin (RR 0.96, 95% CI 0.65 to 1.41; 6 trials, 1689 participants; moderate-certainty evidence). (PMIDs: 37818733) [PMID 37818733]
• In the provided Cochrane review update, serious adverse events were reported as showing little to no difference in the total number of people with SAEs (RR 1.16, 95% CI 0.81 to 1.66; 3 trials, 1335 participants; moderate-certainty evidence), with an increase in total non-fatal serious adverse events (RR 2.39, 95% CI 1.10 to 5.23; 3 trials, 1335 participants; moderate-certainty evidence), and subgroup findings described for a specific dosing schedule. (PMIDs: 37818733) [PMID 37818733]
• In the earlier Cochrane review (searched May 2016), it was reported that six randomized controlled trials (1501 participants) met inclusion criteria for acute ischaemic stroke, and it summarized outcomes including all-cause death (RR 0.91, 95% CI 0.61 to 1.35; 5 trials, 1417 participants) and serious adverse events (RR 1.16, 95% CI 0.81 to 1.67) with an increase in non-fatal SAEs. (PMIDs: 28430363) [PMID 28430363]
• An analysis comparing Cerebrolysin with several peptide preparations allegedly similar to it reported that these preparations lacked relevant biological activity and had peptide composition significantly different from Cerebrolysin. (PMIDs: 38737662) [PMID 38737662]
• A proteomic study of a 'light' peptide fraction of Cerebrolysin reported identification of 14,635 peptides corresponding to porcine proteome neuronal proteins, and described that analysis suggested fragments could correspond to known biologically active peptides and could modulate human signaling proteins (including multiple named proteins/pathway-related targets). (PMIDs: 31626174) [PMID 31626174]
• A review/discussion paper reported that nanowired delivery approaches combining monoclonal antibodies (to amyloid beta peptide, phosphorylated tau, and TNF-α) with cerebrolysin in sleep-deprivation-induced AD pathology resulted in 'superior neuroprotection' in the authors’ investigations. (PMIDs: 37480458) [PMID 37480458]
• A study reported that sleep deprivation enhanced amyloid beta peptide burden, phosphorylated tau, and serotonin, and that nanowired delivery of cerebrolysin together with monoclonal antibodies to amyloid beta peptide, phosphorylated tau, and serotonin reduced the observed sleep-deprivation-induced pathophysiology in the authors’ investigation. (PMIDs: 37783554) [PMID 37783554]
• A review reported that in a traumatic brain injury (TBI) exacerbation context for AD neuropathology, observations based on the authors’ investigations described that nanowired delivery of mesenchymal stem cells together with cerebrolysin and monoclonal antibodies to amyloid beta protein thwarted development of neuropathology following TBI in AD. (PMIDs: 34560919) [PMID 34560919]
• An investigation reported that spinal cord injury was associated with increased amyloid beta peptide and phosphorylated tau in spinal cord segments and remote brain/spinal cord areas, and it reported that repeated nanowired delivery of cerebrolysin together with monoclonal antibodies attenuated amyloid beta peptide and phosphorylated tau deposition and reduced inflammatory markers and barrier-related outcomes in the authors’ observations. (PMIDs: 37833015) [PMID 37833015]